Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample

1. A method for predicting the aggressiveness or indolence of prostate cancer in a patient previously diagnosed with prostate cancer, comprising the steps of:

obtaining a blood-based sample from the prostate cancer patient;

conducting mass spectrometry of the blood-based sample with a mass spectrometer and thereby obtaining mass spectral data including intensity values at a multitude of m/z features in a spectrum produced by the mass spectrometer;

performing pre-processing operations on the mass spectral data;

classifying the sample with a programmed computer implementing a classifier operating on the intensity values of the sample after the pre-processing operations are performed and a set of stored intensity values of m/z features from a constitutive set of mass spectra obtained from blood-based samples of a multitude of prostate cancer patients; wherein the classifier is defined from one or more master classifiers generated as a combination of filtered mini-classifiers with regularization, wherein the mini-classifiers execute a K-nearest neighbor classification algorithm on a set of features selected from the list of features set forth in Example 1 Appendix A, Example 2 Appendix A, or Example 3 Appendix A, wherein the classifier produces a class label for the blood based sample of High, Early, or the equivalent signifying the patient is at high risk of early progression/relapse of the prostate cancer indicating aggressiveness of the prostate cancer, or Low, Late or the equivalent, signifying that the patient is at low risk of early progression/relapse of the prostate cancer indicating indolence of the prostate cancer.

2. The method of claim 1 , wherein the classifier is defined from one or more master classifiers generated by conducting logistic regression with extreme drop-out on a multitude of mini-classifiers which meet predefined filtering criteria.

3. The method of claim 1 , wherein non-mass spectral information on the patient whose sample is tested in claim 1 is obtained, including at least one of age, PSA and % fPSA, wherein such non-mass spectral information is also obtained for each prostate cancer patient whose blood-based sample is a member of the constitutive set and stored in a computer memory, and wherein the final classifier uses such non-mass spectral information in addition to the mass spectral data when generating a class label for the sample.

4. The method of claim 1 , wherein each prostate cancer patient whose sample is a member of the constitutive set supplied the sample after diagnosis with prostate cancer but before radical prostatectomy (RPE).

5. The method of claim 1 , wherein each prostate cancer patient whose sample is a member of the constitutive set has a Total Gleason Score of 6 or lower at the time the blood-based sample from such patient was obtained.

6. The method of claim 1 , wherein the mass spectrum of the blood-based sample is obtained from at least 100,000 laser shots applied to the sample using MALDI-TOF mass spectrometry.